Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.8K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

17.4K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.4K
Autoimmune Disorders01:29

Autoimmune Disorders

1.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.9K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

225
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limitations of ultrasonography in the assessment of aortic involvement in giant cell arteritis: comment on the article by Bull Haaversen et al.

Arthritis care & research·2026
Same author

Rare Gain-of-Function Variants in IDH1 and IDH2 Confer Increased Risk of Immune-Mediated Rheumatic Diseases.

ACR open rheumatology·2026
Same author

Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Type I interferon drives dysfunction of a distinct CD8+ HLA-DRB1+ T cell subset in systemic lupus erythematosus.

medRxiv : the preprint server for health sciences·2026
Same author

DNA Methylation Profiling Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Patterns Associated With Sex and Disease Activity in Childhood-Onset Lupus.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

DNA Methylation Profiling in Childhood-Onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Nov 19, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.2K

SARS-CoV-2 and Systemic Lupus Erythematosus.

Aikaterini Thanou1, Amr H Sawalha2

  • 1Arthritis and Clinical Rheumatology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, MS 22, Oklahoma City, OK, 73104, USA. aikaterini-thanou@omrf.org.

Current Rheumatology Reports
|January 29, 2021
PubMed
Summary

The impact of coronavirus disease 19 (COVID-19) on patients with systemic lupus erythematosus (SLE) is not fully understood due to study limitations. Current data suggest corticosteroids may increase hospitalization risk, while other immunosuppressants show limited impact.

Keywords:
COVID-19ImmunosuppressionSystemic lupus erythematosus

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

627

Related Experiment Videos

Last Updated: Nov 19, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.2K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

627

Area of Science:

  • Rheumatology and Immunology
  • Infectious Diseases

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems.
  • The emergence of coronavirus disease 19 (COVID-19) has raised concerns for patients with chronic autoimmune conditions.
  • Understanding COVID-19's impact on SLE patients is crucial for clinical management and patient safety.

Purpose of the Study:

  • To review and summarize current knowledge regarding the effects of COVID-19 in patients diagnosed with SLE.
  • To identify gaps in the existing research on COVID-19 outcomes in SLE populations.

Main Methods:

  • Review of observational studies, including case series, patient surveys, and registries.
  • Analysis of reported incidence, severity, and outcomes of COVID-19 in SLE patients.
  • Assessment of the influence of SLE treatments on COVID-19 risk and prognosis.

Main Results:

  • Methodological limitations in current studies hinder definitive conclusions about COVID-19 risk and outcomes in SLE patients.
  • Corticosteroid use may be linked to increased COVID-19 hospitalizations in autoimmune rheumatic diseases.
  • Some immunosuppressive therapies may not significantly elevate COVID-19 infection risk or adverse outcomes, but data are scarce.
  • Ethnic and racial minorities, disproportionately affected by SLE, experience more severe COVID-19, potentially due to socioeconomic factors and comorbidities.
  • The interaction between SARS-CoV-2 and the SLE immune environment requires further investigation.
  • Concerns exist regarding heightened thromboembolic risk in SLE patients with COVID-19 due to a procoagulant state.

Conclusions:

  • Current epidemiologic data are insufficient to accurately assess COVID-19 risk and severity in SLE patients.
  • Beyond corticosteroids, the impact of most immunosuppressants on SARS-CoV-2 infection risk needs more comprehensive study.
  • Further research is essential to elucidate the specific implications of COVID-19 for individuals with systemic lupus erythematosus.